CLINICAL STUDIES

BASECAMP-1: a pre-screening study

BASECAMP-1 is a pre-screening study to identify patients for potential treatment in our clinical trials.

BASECAMP-1 is currently enrolling patients with mesothelioma or colorectal, non-small cell lung, pancreatic, or ovarian cancers.

Objective: use next-generation sequencing to identify patients with solid tumors that have lost human leukocyte antigen (HLA), then perform leukapheresis (removal of blood to collect specific blood cells) to collect, process, and store patient T-cells for future Tmod™ CAR T-cell therapy.

Study design: non-interventional, observational study to evaluate patients with solid tumors at a high risk of relapse. Participants who meet the criteria may be enrolled and undergo leukapheresis. Patients’ cells will be processed and stored for potential manufacture of Tmod™ CAR T-cell therapy upon relapse of their cancer.

Study centers recruiting for BASECAMP-1 can be found here: Locations

Further information about this study can be found here: NCT04981119

Understanding BASECAMP-1

EVEREST-1: a phase 1/2 study for solid tumors that express carcinoembryonic antigen (CEA)

EVEREST-1 is a phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of A2B530, an autologous logic-gated Tmod™ CAR T-cell therapy.

EVEREST-1 is currently enrolling patients with recurrent unresectable, locally advanced, or metastatic colorectal, non-small cell lung, or pancreatic cancers, or other solid tumors that express the biomarker CEA.

Objective: to evaluate the safety and tolerability of A2B530, and identify the maximum tolerated and recommended doses.

Study design: phase 1/2, US-based, multicenter, open-label, non-randomized, dose-escalation study to evaluate germline heterozygous HLA-A*02 recurrent unresectable, locally advanced, or metastatic colorectal, non-small cell lung, or pancreatic cancers. Patients will initially be enrolled in the BASECAMP-1 pre-screening study and undergo leukapheresis before entering EVEREST-1.

Study centers recruiting for EVEREST-1 can be found here: Locations

Further information about this study can be found here: NCT05736731

EVEREST-2: a phase 1/2 study for solid tumors that express mesothelin (MSLN)

EVEREST-2 is a phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of A2B694, an autologous logic-gated Tmod™ CAR T-cell therapy.

EVEREST-2 is currently enrolling patients with recurrent unresectable, locally advanced, or metastatic mesothelioma, colorectal, non-small cell lung, pancreatic, or ovarian cancers; or other solid tumors that express the biomarker MSLN.

Objective: to evaluate the safety and tolerability of A2B694, and identify the maximum tolerated and recommended doses.

Study design: phase 1/2, US-based, multicenter, open-label, non-randomized, dose-escalation study to evaluate germline heterozygous HLA-A*02 recurrent unresectable, locally advanced, or metastatic mesothelioma or colorectal, non-small cell lung, pancreatic, or ovarian cancers. Patients will initially be enrolled in the BASECAMP-1 pre-screening study and undergo leukapheresis before entering EVEREST-2.

Study centers recruiting for EVEREST-2 can be found here: Locations

Further information about this study can be found here: NCT06051695